Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trading Halts

FDA's Letter to Heron Therapeutics (HRTX) Over Sustol ApprovalAugust 10, 2016 12:50 PM FDA Approval of Heron Therapeutics' (HRTX) Sustol Removes Major Overhang - AnalystAugust 10, 2016 11:14 AM Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and VomitingAugust 10, 2016 8:30 AM